Semaglutide, a glucagon-like peptide‑1 receptor agonist (GLP‑1 RA) marketed globally as Ozempic, Wegovy, and Rybelsus, has transformed the pharmacological management of type 2 diabetes and obesity, often achieving weight loss previously seen only with bariatric surgery. India, which now ranks among the highest in the world for both diabetes and obesity, has begun to integrate semaglutide (oral and injectable forms) into clinical practice, with domestic manufacturers preparing generic versions as patents expire. This article situates semaglutide within India’s socio‑cultural and psychological landscape, examining how the drug intersects with body image, internalised weight stigma, mental health, health‑seeking behaviour, and structural determinants of “diabesity.” Drawing on international psychopharmacology and safety data as well as Indian clinical and policy literature, it argues that semaglutide can be a powerful tool but also risks deepening moralised narratives of weight, widening inequities, and narrowing public imagination to a pharmacological solution. Psychological practice in India must therefore accompany semaglutide use with stigma‑aware, culturally grounded, and structurally informed care.

1. Introduction: Diabesity and the Semaglutide Moment

India is facing overlapping epidemics of diabetes and obesity—often termed “diabesity”—with one recent review noting that the country holds the second‑highest global burden of diabetes and the third‑highest burden of obesity. National survey data (NFHS‑5) indicate that around 24% of women and 23% of men aged 15–49 are overweight or obese, with rates climbing much higher in urban, higher‑income groups. Rising central obesity in Indian women over 35 further amplifies cardiometabolic risk and, by extension, the urgency of effective interventions.

Semaglutide, originally developed for glycaemic control in type 2 diabetes, has emerged as a so‑called “game changer” in obesity pharmacotherapy because weekly 2.4 mg injections can produce average weight loss of 15% or more in many patients, outstripping older medications. Beyond weight reduction, semaglutide improves cardiovascular and renal outcomes and alleviates heart failure symptoms, expanding its appeal as a multi‑benefit drug.

In India, oral semaglutide (Rybelsus) is already in use for diabetes, and regulatory approvals for injectable semaglutide brands (including Ozempic and Wegovy) have been followed by plans for domestic generic launches once patents lapse. Simultaneously, media discourse and social media have framed GLP‑1 drugs as aspirational “weight‑loss injections,” with India Today describing the country’s entry into the “injectable era of weight loss” amid intense social pressure to be thin or “fit.”

Against this backdrop, semaglutide is not just a pharmacological molecule; it is a psychological and cultural event. It shapes and is shaped by how Indians understand fatness, health, self‑discipline, morality, and the body. This article therefore asks: what does semaglutide mean in the Indian psychological context, and how should mental‑health professionals respond?

2. Semaglutide in Brief: Mechanism, Indications, and Indian Availability

2.1 Mechanism and clinical indications

Semaglutide is a long‑acting GLP‑1 receptor agonist that enhances glucose‑dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on central appetite pathways, producing both improved glycaemic control and reduced energy intake. At lower doses, it is approved for type 2 diabetes; at higher doses (2.4 mg weekly), it is approved in several countries for chronic weight management in adults and adolescents with obesity.

2.2 Indian regulatory and market landscape

In India, oral semaglutide has been framed as a way to “overcome barriers of incretinisation” by avoiding injections, which have historically deterred many patients from GLP‑1 therapy. Reviews focused on Indian clinical practice highlight oral semaglutide’s multifaceted benefits—glycaemic control, weight loss, and cardiovascular and renal protection—while emphasising improved adherence due to oral administration.

More recently, India’s drug regulator (CDSCO/DCGI) has approved injectable semaglutide (Ozempic) for type 2 diabetes, adding to an already expanding GLP‑1 portfolio that includes oral Rybelsus and obesity‑focused Wegovy. Media reports describe Wegovy’s launch in India with monthly costs in the range of ₹17,000–₹26,000, positioning it firmly as a high‑end therapy. At the same time, large domestic manufacturers such as Sun Pharma and Dr Reddy’s have secured approval to produce generic semaglutide injections for chronic weight management once Novo Nordisk’s formulation patent expires around March 2026, signifying an anticipated explosion in availability and marketing.

2.3 Adoption barriers and inequities

Despite their promise, GLP‑1 RAs remain under‑utilised in India. A recent review on elevating GLP‑1 RA adoption identifies high cost, limited insurance coverage, low awareness among both patients and providers, and cultural stigma around injectables as central barriers. South Asian consensus recommendations similarly note that regional approval status, out‑of‑pocket payment structures, and heterogeneity in clinical training shape uneven access across the subcontinent.

These structural factors create a psychological landscape of scarcity, moralisation, and aspiration: semaglutide becomes both a coveted symbol of modern medical progress and a reminder of inequality, potentially intensifying feelings of inadequacy among those who cannot access it.

3. Psychological Meanings of Weight and Medication in India

3.1 Weight, morality, and identity

Obesity in India is not experienced only as a biomedical state; it is deeply entangled with ideas of self‑control, virtue, and social worth. Public discourse frequently frames weight gain as a failure of willpower or lifestyle discipline, even though structural drivers—urban design, food environments, labour precarity, and gendered domestic burdens—play major roles. NFHS‑5 data reveal that overweight and obesity disproportionately affect urban, higher‑income, and often higher‑caste groups, creating further complexity: fatness can be read simultaneously as a sign of affluence and as moral failure.

Within this moral economy, semaglutide may function psychologically not just as treatment but as redemption. A pharmacological agent that suppresses appetite and produces reliable weight loss can be seen as restoring lost self‑control, repairing shame, or finally aligning the body with internalised ideals. Media narratives that celebrate “transformations” on Wegovy or Ozempic reinforce a storyline of redemption through pharmaceutical intervention.

3.2 Body image, internalised stigma, and eating pathology

Weight‑loss drugs emerge into a culture already saturated with narrow beauty standards and thin‑ideal messaging, especially for women. Indian media and advertising often valorise slim, fair, and youthful bodies, while fatness—particularly in women—is portrayed as undesirable, lazy, or unlovable. These representations contribute to internalised weight stigma, where individuals adopt society’s negative stereotypes about their own bodies, which in turn predicts depression, disordered eating, and reduced healthcare engagement.

GLP‑1 drugs like semaglutide offer visible body changes that may temporarily alleviate appearance‑related distress but can also reinforce the idea that only thinner bodies are acceptable. Qualitative accounts from global settings describe individuals feeling pressure to maintain medication‑induced weight loss at all costs, fearing social judgment if weight returns when treatment stops. In India, where arranged marriages and family negotiations still often hinge on women’s appearance and body size, semaglutide‑driven weight changes may become entangled with marital prospects and family honour, amplifying psychological stakes.

There is also a risk that pharmacological appetite suppression can mask, rather than resolve, underlying eating pathology. For individuals with binge‑eating tendencies, emotional overeating, or history of restrictive dieting, semaglutide may reduce binge frequency but leave intact the cognitive distortions, shame, and affect regulation difficulties that maintain disordered eating. Without psychological support, cessation or plateauing of weight loss may trigger intense distress and renewed cycles of extreme dieting or medication shopping.

4. Mental Health Outcomes: Evidence and Uncertainties

4.1 Emerging safety signals and large‑scale data

As semaglutide’s use has scaled, reports of potential psychiatric adverse events—particularly depression and suicidal ideation—have attracted regulatory scrutiny. An analysis of the WHO pharmacovigilance database reported a slightly higher‑than‑expected number of suicidal ideation reports for semaglutide when compared with metformin and an SGLT2 inhibitor, especially among people also using antidepressants or benzodiazepines, and called for urgent clarification.

However, larger controlled analyses have not found evidence that semaglutide increases suicidal thoughts relative to other treatments. A study using US electronic health records for over 240,000 people with overweight or obesity reported that 0.11% of those prescribed semaglutide experienced suicidal thoughts within six months, compared with 0.43% among those on non‑GLP‑1 anti‑obesity drugs. Among more than 1.5 million people with type 2 diabetes, semaglutide was again associated with lower risk of suicidal ideation compared with non‑GLP‑1 medications.

Similarly, a JAMA Internal Medicine analysis led by Penn Medicine researchers found that in people without known major mental‑health disorders, taking semaglutide for weight loss did not increase depressive symptoms or suicidal thoughts or behaviours. These findings suggest that, at a population level, semaglutide may not confer added psychiatric risk and might even be associated with lower risk, possibly via improvements in weight‑related stigma, metabolic health, and function.

4.2 Case reports and clinical vigilance

Despite reassuring aggregate data, individual case reports raise important cautionary notes. A published report described a man with type 2 diabetes who developed restlessness and depressed mood after initiating semaglutide; his symptoms improved once the drug was discontinued, prompting the authors to urge regular monitoring of depression, anxiety, and suicidal ideation in semaglutide‑treated patients. Such reports cannot establish causality but highlight the need for psychological assessment rather than assuming purely peripheral metabolic effects.

For Indian clinicians, where mental‑health screening in diabetes clinics is often minimal, the combination of rare but serious potential adverse effects and strong social pressure around weight loss makes proactive assessment ethically important. Asking about mood, anxiety, eating patterns, and suicidality before and during semaglutide therapy should be standard, especially for individuals with past psychiatric history or high levels of weight‑related shame.

5. Social Acceleration: Media, Market, and the “Injectable Era” in India

5.1 GLP‑1 drugs as cultural objects

Media narratives in India increasingly position GLP‑1 drugs as lifestyle technologies rather than only as chronic‑disease treatments. India Today describes once‑weekly injectables like Wegovy and tirzepatide (Mounjaro) as part of a broader “race” for rapid weight loss, fuelled by celebrity endorsements and viral global trends. Sales data reveal explosive growth, with Mounjaro reportedly selling over 81,500 units and generating roughly ₹239 million in revenue within a short period, and Wegovy priced at tens of thousands of rupees per month.

Such framing constructs semaglutide as a symbol of modernity, efficiency, and even luxury. Weight loss becomes a competitive project, and the drug becomes a marker of participation in that project. For urban, upper‑middle‑class Indians who can afford these therapies, semaglutide may signal not only self‑improvement but also classed distinction—another form of “wellness capital.” Those unable to access it may feel left behind or morally blamed for not “doing everything” possible to lose weight.

5.2 Social media, comparison, and body surveillance

Internationally, platforms like TikTok and Instagram have been saturated with “Ozempic” content—before‑and‑after photos, daily side‑effect diaries, and tips for maximising weight loss. Although India‑specific data on GLP‑1 social media narratives are limited, Indian users are embedded in the same global feeds, and Indian influencers increasingly discuss these drugs as part of aesthetic and wellness routines.

From a psychological standpoint, this visibility intensifies body surveillance and social comparison. Frequent exposure to dramatic weight‑loss narratives can distort expectations, making modest or slow changes feel like failure and leading individuals to push dose escalation or polypharmacy. It also narrows the definition of “success” to visible thinness, sidelining non‑scale outcomes such as improved stamina, sleep, mood, or glycaemic indices. For people with limited access, watching others pharmacologically transform their bodies may deepen envy, self‑disgust, or despair.

6. Health‑Seeking Behaviour and Structural Context in India

6.1 Barriers beyond individual motivation

Indian literature on GLP‑1 RA adoption emphasises that low uptake is not simply a matter of patient “inertia” but of structural constraints. High out‑of‑pocket costs, scant insurance coverage for chronic‑disease drugs, and patchy availability outside major urban centres all limit access. Cultural skepticism about injections and fears of dependence also influence choices, as do clinicians’ own unfamiliarity or discomfort with newer agents.

A recent review proposing the CLIBS model for India—focusing on Cost‑effectiveness, Long‑term data, Insurance reform, Benefits communication, and Social media impact—argues that without addressing these system‑level issues, GLP‑1 uptake will remain restricted to a small elite, reinforcing disparities in metabolic and mental health. Psychological interventions that focus solely on motivation or adherence risk mislocating responsibility for non‑use onto individuals rather than systems.

6.2 Real‑world Indian data and patient experience

Real‑world analyses of oral semaglutide in Indian adults with type 2 diabetes support its effectiveness in routine practice. An electronic medical‑record‑based study of 188 Indian patients found statistically significant reductions in HbA1c (0.34 percentage points on average), body weight (1.83 kg), and BMI (0.73 kg/m²) over approximately 114 days, along with modest blood pressure improvements. Earlier reviews similarly highlight that oral administration may improve adherence compared with injectables in Indian settings.

While these studies primarily focus on biomedical endpoints, their implications are psychological. Improved glycaemic control and modest weight loss can reduce fatigue, physical discomfort, and self‑blame, potentially easing depressive symptoms and enhancing self‑efficacy. However, when expectations are inflated by media narratives promising dramatic transformation, such modest changes may feel disappointing, undermining motivation and increasing mistrust in both physicians and medications.

7. Ethical and Developmental Questions: Children, Adolescents, and Medicalisation

Although paediatric obesity is already a major concern in high‑income countries, India is also seeing rising rates of childhood overweight in urban areas, raising the question of whether semaglutide will eventually be considered for younger populations. An ethical review of semaglutide use in children in Europe foregrounds concerns about long‑term safety, impacts on growth and development, and the risk of shifting focus away from structural determinants such as food systems and poverty.

From a psychological perspective, introducing weight‑loss injections in adolescence risks entrenching weight‑centric identity and externalising body regulation. Young people may learn to view their bodies as problems to be pharmacologically fixed rather than as sites of complex social, emotional, and cultural meaning. In India’s exam‑ and marriage‑oriented social climate, adolescents already face intense performance and appearance pressures; adding injectable weight‑loss drugs into this matrix could amplify body dissatisfaction, perfectionism, and conditional self‑worth.

Ethical practice would therefore demand stringent safeguards: prioritising family‑ and school‑based interventions; ensuring that any pharmacotherapy is embedded in holistic care that addresses bullying, stigma, and mental health; and recognising the limits of individual behaviour or pharmacology in the face of obesogenic environments.

8. Clinical Implications for Psychologists and Mental‑Health Practitioners in India

8.1 Assessment: Beyond kilograms and HbA1c

For Indian psychologists, semaglutide’s growing presence requires updating assessment frameworks. Intake and follow‑up assessments with clients who have diabetes, obesity, or polycystic ovary syndrome (PCOS) should routinely include questions about pharmacological treatments, including GLP‑1 drugs, and their psychological meanings. Relevant dimensions include:

• Body image and internalised weight stigma (e.g., self‑loathing, disgust, shame).
• Eating patterns (binge episodes, restriction, emotional eating, night eating).
• Mood and anxiety symptoms, with explicit exploration of hopelessness and suicidality.
• Expectations from medication (“cure,” exact target weight, time frames) and fear of weight regain.
• Social context: family attitudes to weight, marriage pressures, workplace discrimination, social‑media exposure.

Clinicians should be particularly attentive to clients who see semaglutide as their “lastchance” or who link their worth or marriageability directly to drug‑induced weight loss, as these cognitions can intensify distress with any lapse or plateau.

8.2 Intervention: Integrating pharmacotherapy with psychological care

Evidence from obesity and diabetes psychology suggests that pharmacological interventions are most effective and sustainable when combined with behavioural and psychosocial support. In India, where counselling resources in endocrinology settings are scarce, psychologists can play multiple roles:

• Psychoeducation: framing semaglutide as one tool in a broader care plan; clarifying realistic trajectories of weight change; emphasising non‑scale benefits (mobility, glycaemic control, sleep) to avoid all‑or‑nothing thinking.
• Stigma‑reduction work: helping clients recognise and challenge internalised anti‑fat attitudes; exploring how caste, class, gender, and colourism intersect with body ideals.
• Cognitive‑behavioural strategies: addressing dichotomous thinking around food and weight, perfectionism, and body‑checking; supporting flexible, values‑consistent behaviour rather than rigid rule‑following.
• Emotion‑focused and trauma‑informed approaches: exploring how food has functioned as comfort, protection, or rebellion in contexts of violence, neglect, or marginalisation.
• Relapse prevention: preparing clients for plateaus, side‑effects, or discontinuation; developing coping plans for possible partial weight regain, thereby reducing catastrophic interpretations.

Interdisciplinary collaboration—where psychologists communicate with endocrinologists or physicians (with client consent)—can also facilitate shared decision‑making about dose changes or discontinuation when mental‑health concerns arise.

8.3 Ethical communication and consent

Given aggressive global marketing and aspirational media narratives, informed consent around semaglutide in India requires explicit attention to psychological and social dimensions. Ethical communication should include:

• Clear discussion of benefits and limitations, including the likelihood that long‑term weight maintenance may require ongoing medication and/or sustained lifestyle changes.
• Disclosure of known and uncertain psychiatric risks, however small, and a plan for regular mental‑health monitoring.
• Exploration of how the patient’s goals relate to broader values (health, mobility, participation in family or community life) rather than only to appearance or external validation.
• Recognition of structural constraints: cost, insurance, work schedules, caregiving responsibilities, and food access. Patients should not be made to feel individually responsible for discontinuing a medication they cannot afford.

Psychologists can support clients in preparing questions for their diabetologists or obesity specialists, thus enhancing autonomy and reducing power asymmetries in consultations.

9. Broader Societal and Policy Considerations

9.1 Avoiding the trap of pharmacological solutionism

A central psychological risk of the semaglutide era is pharmacological solutionism: the belief that a powerful drug renders broader structural and cultural changes unnecessary. Reviews of anti‑obesity pharmacotherapy warn that even very effective medications cannot by themselves reverse obesogenic environments, which are shaped by urban design, food marketing, labour policies, and social inequities.

In India, where ultra‑processed foods have rapidly penetrated rural and urban markets and sedentary work has expanded, a narrow focus on individual behaviour and medication risks reinforcing narratives of blame toward people living with obesity or diabetes. This may undermine public support for upstream interventions such as taxation of sugary beverages, zoning regulations to increase walkable spaces, school‑meal reforms, or labour protections that allow time for physical activity.

9.2 Equity, caste, gender, and region

Semaglutide’s high cost and concentration in private urban healthcare settings mean that the people most able to access it are often those already relatively advantaged by caste, class, and geography. Meanwhile, poorer and rural populations, who may experience undernutrition early in life followed by low‑quality obesogenic diets later, continue to bear a disproportionate burden of metabolic disease without access to cutting‑edge therapies.

Psychologically, this stratification can create a two‑tier imaginary of health: one in which a slim, medicated, gym‑going urban elite embodies the aspirational ideal, and another in which larger, sicker, and poorer bodies are pathologised and neglected. Any ethical integration of semaglutide in India must therefore be embedded in policies aimed at strengthening public primary care, expanding insurance coverage, and addressing social determinants of health rather than treating pharmacological innovation as an end in itself.

10. Future Directions for Research and Practice

10.1 Research gaps in the Indian context

Although there is growing Indian literature on the clinical effectiveness of oral semaglutide, very little empirical work has examined its psychological impacts in India. Existing studies focus primarily on biomedical endpoints—HbA1c, weight, blood pressure—without assessing changes in body image, self‑stigma, quality of life, or mental‑health symptoms. Future research should therefore prioritize:

• Longitudinal mixed‑methods studies of Indian semaglutide users assessing mood, anxiety, self‑esteem, and stigma, alongside biomedical outcomes.
• Qualitative work exploring lived experience: motivations for starting semaglutide, family and community reactions, experiences of side‑effects, and meanings attached to weight change.
• Comparative studies across socio‑economic, caste, gender, and regional groups to understand how structural position shapes access, expectations, and psychological outcomes.
• Specific studies in sub‑populations such as adolescents, people with severe mental illness, and those with diagnosed eating disorders, given their distinct vulnerabilities.

10.2 Training and curriculum for psychologists

Indian psychology training rarely covers psychopharmacology for metabolic conditions or the psychosocial dimensions of obesity beyond generic “lifestyle” advice. Incorporating modules on diabesity, GLP‑1 agents, and weight stigma into clinical and counselling psychology curricula would better prepare future professionals. Such training should foreground:

• Critical perspectives on anti‑fat bias and medicalisation.
• Skills for collaborative work with endocrinologists, nutritionists, and bariatric surgeons.
• Competence in culturally sensitive body‑image and eating‑disorder interventions tailored to Indian contexts (e.g., negotiating food practices within joint families, navigating marriage‑related pressures).

Continuing education for practicing clinicians—via workshops, webinars, or interdisciplinary case conferences—can help bridge current gaps in knowledge and comfort around semaglutide‑related issues.

11. Conclusion

Semaglutide arrives in India at a time when diabesity has become both an epidemiological crisis and a cultural preoccupation. Evidence from clinical trials and emerging real‑world data suggests that semaglutide can deliver meaningful improvements in glycaemic control and weight, with generally favourable psychiatric safety profiles at the population level. At the same time, media narratives and market forces risk recasting it as a quick‑fix tool in a high‑pressure race for thinness, overshadowing issues of stigma, inequality, and structural determinants of health.

From a psychological standpoint, semaglutide is best understood not as a standalone solution but as one element in a complex ecology of bodies, identities, and institutions. For India, an ethical path forward would integrate semaglutide into multidisciplinary care that foregrounds mental health, addresses internalised and structural weight stigma, and advocates for policy changes that make metabolic health achievable without pharmaceutical access being the dividing line between the privileged and the excluded. Psychologists, working alongside physicians and public‑health practitioners, have a critical role in ensuring that the semaglutide moment becomes an opportunity to reimagine care in ways that centre dignity, equity, and psychological well‑being.

References

Business Today. (2025, September 26). Ozempic gets India nod: Drug regulator approves Novo Nordisk’s blockbuster diabetes drug. Business Today. https://www.businesstoday.in/india/story/ozempic-gets-india-nod

Colin, I. M. (2022). Once-weekly 2.4 mg semaglutide for weight management in obesity: A game changer? Touch Endocrinology, 18(1), 35–42.

India Today. (2025, June 26). Thin at what cost? The mental toll of the weight-loss race. India Today. https://www.indiatoday.in/health/story/thin-at-what-cost

International Institute for Population Sciences. (2021). National Family Health Survey (NFHS-5), 2019–21: India report. Ministry of Health and Family Welfare. https://rchiips.org/nfhs/

Mehta, S., et al. (2024). Real-world effectiveness of oral semaglutide in Indian adult diabetic patients. Journal of Diabetes Research. https://discovery.researcher.life/article/real-world

National Institutes of Health. (2026, February 17). People taking semaglutide had lower risk of suicidal thoughts. NIH Research Matters. https://www.nih.gov/news-events/nih-research-matters

Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Das, A. K., & Unnikrishnan, A. G. (2022). First-in-class oral semaglutide: Overcoming barriers of incretinisation in the Indian context. Indian Journal of Endocrinology and Metabolism, 26(5), 417–426. https://doi.org/10.4103/ijem.ijem_217_22

Sun Pharmaceutical Industries Ltd. (2026, January 22). Sun Pharma gets DCGI nod for generic semaglutide [Press release]. https://sunpharma.com

Sundararajan, S., et al. (2024). Semaglutide and beyond: A turning point in obesity pharmacotherapy. Obesity Pillars, 9, Article 100099. https://doi.org/10.1016/j.obpill.2024.100099

U.S. Food and Drug Administration. (2024). Semaglutide: Safety communication on psychiatric events. https://www.fda.gov